U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Science & Research
  3. About Science & Research at FDA
  4. FDA Grand Rounds
  5. Immune System Responses to Therapeutic Proteins: Getting up close and personal - 09/09/2021
  1. FDA Grand Rounds

Webcast | Virtual

Event Title
Immune System Responses to Therapeutic Proteins: Getting up close and personal
September 9, 2021

Date:
September 9, 2021
Organized By:
Organizer

About the Speaker:

Zuben E. Sauna, PhD
Research Biologist
Division of Plasma Protein Therapeutics 
Office of Tissues and Advanced Therapies
Center for Biologics Evaluation and Research (CBER)

Zuben E. Sauna is a Principal Investigator and a Chemistry, Manufacturing and Controls Reviewer at the US Food and Drug Administration. His research interests lie in understanding the pharmacogenetic basis of the immune response to proteins used in therapeutic interventions as these affect efficacy and safety. His laboratory exploits a combination of computational, in vitro and ex vivo approaches to understand why some individuals and/or sub-populations develop immune responses while others do not. Work from his laboratory has been published in high impact journals such as Nature Biotechnology, Nature Medicine, Science, Science Translational Medicine and Nature Reviews Genetics. He received his Ph.D. from Poona University, India. 

About the Presentation:

Proteins used as therapeutics have become an essential part of modern medicine. Immunogenicity (anti-drug antibodies that target the protein-therapeutic) is a significant impediment to development and licensure of any therapeutic-protein. The lecture will illustrate how judicious application of tools available for immunogenicity risk-assessment can permit better decision-making during drug-development, licensure, and clinical-trials.

Learning Objectives:

After completion of this activity, the participant will be able to:

  • Identify the economic and personal costs of immunogenicity to protein therapeutics
  • Explain the use of non-clinical immunogenicity assays for determining immunogenicity risk
  • List some in silico, in vitro and ex vivo methods used to evaluate immunogenicity of therapeutic proteins

Webcast Recording:

https://collaboration.fda.gov/prcg2an2fwbr/

Event Materials:

Activity Outline FDA Grand Rounds: September 9, 2021

For technical assistance please contact: Niccole.Corbin@fda.hhs.gov

 www.FDA.gov/GrandRounds  

Event Materials

Title File Type/Size
Activity Outline FDA Grand Rounds: September 9, 2021 pdf (215.71 KB)
Back to Top